Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has mat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:CPT Pharmacometrics Syst Pharmacol
Autores principales: Stroh, M, Carlile, DJ, Li, C-C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J-E, Xhu, Z-X, Morcos, PN, Davis, JD, Phipps, A
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Perspective
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4592528/
https://ncbi.nlm.nih.gov/pubmed/26451328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12014
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares